How to handle benign optic glioma of childhood: A short overview
Neuro-Ophthalmology, ISSN: 0165-8107, Vol: 33, Issue: 3, Page: 106-109
2009
- 15Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures15
- Readers15
- 15
Article Description
Optic glioma is a rare benign tumour predominantly occurring in childhood, frequently associated with Neurofibromatosis Type 1 (NF1). It threatens vision andif extending suprachiasmaticallythe life of the patient. Symptoms are visual loss, orbital signs including motility disorders and/or nystagmus in suprachiasmatic lesions. There is no therapy approved in studies with highest evidence. Radiotherapy is most effective in stopping tumour progression but has serious side effects, such as brain developmental anomalies, moya moya syndrome and secondary tumours. Therefore in children younger than 9 and patients with NF1, chemotherapy with vincristine and carboplatine is preferred. Surgery plays only a role in the debulking of large tumours, cosmetic correction or definitive removal if visual function is lost. Therapeutic decisions should be based on reliable function testing.
Bibliographic Details
Informa UK Limited
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know